



Attorney Docket No.: 5697.200-US

PATENT

AFGP/625
JPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Murray et al.

Application No.: 09/551,740

Group Art Unit: 1625

Filed: April 18, 2000

Examiner: Robinson, B.

Confirmation No: 2226

For: New Compounds, their Preparation and Use

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

- | | |
|----------------|--|
| 1. WO 95/17394 | 07/19/2004 HTECKLU1 00000045 141447 09551740 |
| 2. WO 97/36579 | 01 FC:1806 180.00 DA |
| 3. WO 94/01420 | |
| 4. WO 94/13650 | |

5. WO 95/03038
6. WO 91/19702
7. WO 96/04620
8. US Patent No. 5,306,726

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

This supplemental information disclosure statement is being filed **after** the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

Accompanying this supplemental information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). The Examiner is hereby authorized to charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: July 15, 2004




Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE


 FORM PTO-1449
 (Rev. 12-32)

 U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE
Atty. Docket No. **5697.200-US**Serial No. **09/551,740**
 INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Murray et al.**Filing Date **April 18, 2000**Group **1625**

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|--------------------|---------|-------|-------|----------|-------------------------------|
| | 5,306,726 | 4/26/94 | Hulin | 514 | 375 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|--------------------|----------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | 95/17394 | 6/29/95 | WO | | | | |
| | 97/36579 | 10/9/97 | WO | | | | |
| | 94/01420 | 1/20/94 | WO | | | | |
| | 94/13650 | 6/23/94 | WO | | | | |
| | 95/03038 | 1/2/95 | WO | | | | |
| | 91/19702 | 12/26/91 | WO | | | | |
| | 96/04620 | 2/15/96 | WO | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | | |
|--|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Attorney Docket No.: 5697.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Murray et al.

Serial No.: 09/551,740

Group Art Unit: 1625

Filed: April 18, 2000

Examiner: Robinson, B.

Confirmation No: 2226

For: New Compounds, their Preparation and Use

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **July 15, 2004**

Rashida Haji

(name of person mailing paper)

Rashida Haji

(signature of person mailing paper)